Passive immunotherapeutics are important in post exposure prophylaxis and treatment of infectious diseases. Reagents for passive immunotherapy include convalescent sera and monoclonal antibodies (mAb). Murine, humanized and fully human mAb (fhmAb) share advantages with respect to defined specificity, and enhanced safety profiles. However, only fhmAb possess native effector functions and eliminate risk of immune responses to nonhuman components that have the potential to reduce efficacy and/or cause autoimmune disease. FhmAb that neutralize Rift Valley fever virus (RVFV), Nipah/Hendra virus (NiV/HeV), and West Nile virus (WNV) were created using a fully human fusion partner cell line (MFP-2) and PEL from patients after natural infection (NiV and WNV) or vaccination (RVFV).
In Aim 1 of this project we will characterize these fhmAb in vivo. PBL from immune donors can difficult to obtain, particularly early in the course of an outbreak;thus, alternative strategies are needed whereby fhmAbs with optimized reactivity can be generated using synthetic reagents and in vitro maturation methods. Toward this end we will test (in Aims 2 and 3) the utility of a genetically engineered Veloclmmune? mouse for producing fhmAb from recombinant antigens representing NiV and Chikungunya virus (CHIKV). Functionality of Veloclmmune-drived mAb to NiV will be compared to that of the mAb generated with MFP-2. Furthermore, (Aim 4) we will apply two complementary methods for in vitro optimization of mAb reactivity: a yeast dual-display system that allows for in vitro mutation of cloned sequences followed by high throughput selection of reactive variants in a yeast system, and somatic hypermutation using the Ramos cell and/or activation induced cytidine deaminase (AID) systems.
Specific Aims are: (1) Characterize biological efficacy of existing fhmAb to RVFV, NiV/HeV and WNV;( 2) Generate fhmAb from protective Veloclmmune mAb to NiV and CHIKV;(3) Characterize Veloclmmune immune response and functionality of generated mAb;(4) Use recombinant genetics, mutagenesis, and somatic hypermutation to optimize mAb reactivity.
Passive immunotherapy has an established track record in post exposure prophylaxis and treatment of infectious diseases and will continue to be a significant primary or complementary line of defense. With this project we will generate safe and specific fully human monoclonal antibody (fhmAb) therapeutics for Category A-C agents and establish a universal platform for efficiently generating these tools from entirely synthetic source materials, enabling a swift response to newly identified disease threats.
|Johnson, Joshua C; Martinez, Osvaldo; Honko, Anna N et al. (2014) Pyridinyl imidazole inhibitors of p38 MAP kinase impair viral entry and reduce cytokine induction by Zaire ebolavirus in human dendritic cells. Antiviral Res 107:102-9|
|Gough, Daniel J; Marié, Isabelle J; Lobry, Camille et al. (2014) STAT3 supports experimental K-RasG12D-induced murine myeloproliferative neoplasms dependent on serine phosphorylation. Blood 124:2252-61|
|Kazakov, Teymur; Kuznedelov, Konstantin; Semenova, Ekaterina et al. (2014) The RimL transacetylase provides resistance to translation inhibitor microcin C. J Bacteriol 196:3377-85|
|Rajsbaum, Ricardo; Garcia-Sastre, Adolfo; Versteeg, Gijs A (2014) TRIMmunity: the roles of the TRIM E3-ubiquitin ligase family in innate antiviral immunity. J Mol Biol 426:1265-84|
|Lo, Michael K; Bird, Brian H; Chattopadhyay, Anasuya et al. (2014) Single-dose replication-defective VSV-based Nipah virus vaccines provide protection from lethal challenge in Syrian hamsters. Antiviral Res 101:26-9|
|Mackow, Erich R; Dalrymple, Nadine A; Cimica, Velasco et al. (2014) Hantavirus interferon regulation and virulence determinants. Virus Res 187:65-71|
|Varshney, Avanish K; Wang, Xiaobo; Aguilar, Jorge L et al. (2014) Isotype switching increases efficacy of antibody protection against staphylococcal enterotoxin B-induced lethal shock and Staphylococcus aureus sepsis in mice. MBio 5:e01007-14|
|Chung, Lawton K; Philip, Naomi H; Schmidt, Valentina A et al. (2014) IQGAP1 is important for activation of caspase-1 in macrophages and is targeted by Yersinia pestis type III effector YopM. MBio 5:e01402-14|
|DiLillo, David J; Tan, Gene S; Palese, Peter et al. (2014) Broadly neutralizing hemagglutinin stalk-specific antibodies require Fc?R interactions for protection against influenza virus in vivo. Nat Med 20:143-51|
|Szaba, Frank M; Kummer, Lawrence W; Duso, Debra K et al. (2014) TNF? and IFN? but not perforin are critical for CD8 T cell-mediated protection against pulmonary Yersinia pestis infection. PLoS Pathog 10:e1004142|
Showing the most recent 10 out of 549 publications